nach oben

International Journal of Colorectal Disease

Erschienen in:

01.09.2005 | Original Article

Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study

verfasst von: A. P. Zbar, H. Thomas, R. W. Wilkinson, M. Wadhwa, K. N. Syrigos, E. L. Ross, P. Dilger, T. G. Allen-Mersh, W. A. Kmiot, A. A. Epenetos, D. Snary, W. F. Bodmer

Erschienen in: International Journal of Colorectal Disease | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

The aim was to determine the toxicity, clinical and immune responses to the murine monoclonal anti-carcinoembryonic antigen (CEA) antibody, PR1A3, in patients with advanced colorectal cancer.

Materials and methods

Fifteen patients with advanced colorectal cancer received either 0.5-, 1.0- or 5.0-mg doses of PR1A3 mixed with 10% w/v Alum adjuvant (Superfos Biosector, Denmark) intradermally at 4-week intervals for 3 months. Patient serum was assessed for anti-idiotypic (Ab2), anti-anti-idiotypic (Ab3) and human anti-mouse antibody (HAMA) reactivity. Peripheral blood mononuclear cell (PBMC) proliferation with phytohaemagglutinin (PHA), CEA and PR1A3, stimulated IL-2, IL-4 and IFN-γ levels and PR1A3-stimulated IL-2 receptor expression during immunotherapy were determined. Comparisons were made with 16 age-matched controls without malignant disease.

Results

Hyperimmune sera from 12 of the 15 patients showed Ab2 reactivity with no detectable Ab3 responses. Strong HAMA reactivity was recorded in 7 of the 15 cases with no adverse clinical effect. Delayed-type hypersensitivity (DTH) responses developed in 12 of the 15 patients. Pre-treatment PBMC proliferation with PHA was subnormal in each patient compared with controls, becoming normal (or supranormal) in all patients during immunisation (P<0.001). PBMC proliferation with CEA and PR1A3 increased during immunotherapy (P<0.001) along with stimulated production of IL-2, IFN-γ and IL-2 receptor expression. Progressive disease was observed in 14 of the 15 patients with minimal toxicity.

Conclusion

PR1A3 generated limited idiotypic responses but robust DTH reactivity in most patients. In vitro PBMC proliferation with mitogens and recall antigens is greatly increased during the course of immunisation, with a shift in stimulated cytokine profile.

Mellstedt H (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc) 39 [Suppl]:C1–C16

Mellstedt H, Frodin J-E, Masucci G, Ragnhammar, Fagerberg J, Hjelm AL, Shetye J, Wersall P, Osterborg A (1991) The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 18:462–477PubMed

Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirsch R, Pichlmayr R et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343:1177–1183CrossRefPubMed

Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794PubMed

Punt CJA, Nagy A, Douillard JY et al (2001) Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc Am Soc Clin Oncol 20:123(A)

Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones E, Dethling J, Colman J, Coward L, MacGregor S (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360:671–677CrossRefPubMed

Herlyn D, Koprowski H (1981) Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 27:769–774PubMed

Adams DO, Hall T, Steplewski Z, Koprowski H (1984) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype containing increasing numbers of macrophages activated for distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA 81:3506–3510PubMed

Jerne NK (1974) Towards a network theory of the Immune system. Ann Immunol (Paris) 125C:373–389

10.

Fagerberg J, Frodin J-E, Wigzell H, Mellstedt H (1993) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother 37:264–270CrossRefPubMed

11.

Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M (1995) Immune response to the carcinoembryonic antigen in patients with an anti-idiotype antibody vaccine. J Clin Invest 96:334–352PubMed

12.

Durrant LG, Denton GWL, Jacobs E, Mee M, Moss R, Austin EB, Baldwin RW, Hardcastle JD, Robins RA (1992) An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int J Cancer 50:811–816PubMed

13.

Richman PI, Bodmer WF (1987) Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumor characterization. Int J Cancer 39:317–328PubMed

14.

Lunniss PJ, Skinner S, Britton KE, Granowska M, Morris G, Northover JM (1999) Effect of radioimmunoscintigraphy on the management of recurrent colorectal cancer. Br J Surg 86:244–249CrossRefPubMed

15.

Kim JC, Kim WS, Ryu JS, Oh SJ, Lee DH, Koo KH, Roh SA, Kim HC, Yu CS, Kang GH, Bodmer WF (2000) Applicability of CEA-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma. Cancer Res 60:4825–4829PubMed

16.

Granowska M, Jass JR, Britton KE, Northover JM (1989) A prospective study of the use of ¹¹¹In-labelled monoclonal antibody against CEA in colorectal cancer and of some biological factors affecting its uptake. Int J Colorect Dis 4:97–108

17.

Durbin H, Young S, Stewart LM, Wrba F, Rowan AJ, Snary D, Bodmer WF (1994) An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci USA 91:4313–4317PubMed

18.

Stewart LM, Young S, Watson G, Mather SJ, Bates PA, Band HA, Wilkinson RW, Ross EL, Snary D (1999) Humanisation and characterization of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol Immunother 47:299–306CrossRefPubMed

19.

Begent RHJ, Searle F, Keep PA et al (1986) Operation manual for control, production, preclinical toxicity and phase I trials of anti-tumour antibodies and drug-antibody conjugates. Joint Committee Cancer Research Campaign. Br J Cancer 54:557–568PubMed

20.

Bos JD, van Garderen ID, Krieg SR, Poulter LW (1986) Different in situ distribution patterns of dendritic cells having Langerhans (t6+) and interdigitating (RFD1+) cell immunophenotype in psoriasis, atopic dermatitis and other inflammatory dermatoses. J Invest Dermatol 87:358–361CrossRefPubMed

21.

Betjes MG, Haks MC, Tuk CW, Beelen RH (1991) Monoclonal antibody EBM11 (anti-CD68) discriminates between dendritic cells and macrophages after short-term culture. Immunobiology 183:79–87PubMed

22.

LaFontaine GS, Hansen HJ, Weiss BF et al (1988) Enzyme immunoassay for the detection of circulating immunoglobulins in humans to mouse monoclonal antibody (HAMA). 3rd International Conference of Monoclonal Antibody Immunoconjugates for Cancer, San Diego, 4–6 February 1998. Abstract 77

23.

Kosmas C, Epenetos AA, Courtenay-Luck NS (1991) Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 73:494–500

24.

Neuhaus TJ, Wadhwa M, Callard R, Barratt TM (1995) Increased IL-2, IL-4 and interferon-gamma (IFN-γ) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 100:475–479PubMed

25.

Wadhwa M, Bird C, Dilger P et al (2000) Quantitative biological assays for cytokines. In: Balkwill FR (ed) Cytokine cell biology: a practical approach, 3rd edn. Oxford University Press, Oxford, pp 207–239

26.

Bird C, Wadhwa M, Thorpe R (1991) Development of immunoassays for human IL-3 and IL-4, some of which discriminate between different recombinant DNA-derived molecules. Cytokine 3:562–567CrossRefPubMed

27.

Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, Monson JR, Guillou PJ, Calvert H, Carmichael J, Hardcastle JD (2001) Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 84:1441–1446CrossRef

28.

Gruber R, van Haarlem LJM, Warnaar SO, Holz E, Riethmuller G (2000) The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody 17-1A. Cancer Res 60:1921–1926PubMed

29.

Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M et al (1987) Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84:8055–8059PubMed

30.

Kirman I, Jenkins D, Fowler R, Whelan RL (2003) Naturally occurring antibodies to epithelial cell adhesion molecule (EpCAM). Dig Dis Sci 48:2306–2309CrossRefPubMed

31.

Durrant LG, Buckley DJ, Spendlove I, Robins RA (1997) Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumour T-cell immunity. Hybridoma 16:23–26PubMed

32.

Friguet B, Chaffotte A, Djavadi-Ohanianace L, Godberg ME (1985) Measurements of the true affinity constant in solution of antigen–antibody complexes by ELISA. J Immunol Methods 77:305CrossRefPubMed

33.

Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 21:295–308PubMed

34.

Hjelm Skog AL, Wadhwa M, Hassan M, Gharizadeh B, Bird C, Ragnhammar P, Thorpe R, Mellstedt H (2001) Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody, 17-1A, granulocyte macrophage colony-stimulating factor and IL-2. Clin Cancer Res 7:1163–1170PubMed

35.

Pervin S, Sherratt A, Wang H-T et al (1996) Proliferation of T cells from colon cancer patients with peptides based on the structure of an anti-idiotype antibody mimicking CEA. Am Assoc Cancer Res 37:473–474 (A3231)

36.

Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dorken B, Moldenhauer G (1988) Antibodies as antigens: the use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 167:345–352CrossRefPubMed

37.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clones. I. Definition according to lymphokine activities and secreted proteins. J Immunol 136:2348–2357PubMed

38.

Pellegrini P, Berghella A-M, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Dysregualtion in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1–8CrossRefPubMed

39.

Tsitsilonis OE, Tsavaris NB, Kosmas C, Gouveris P, Papalambros E (2003) Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study. J Chemother 15:387–393PubMed

40.

Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC (1995) Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478–1483PubMed

41.

Takamaku K, Baba K, Arinaga S, Li J, Mori M, Akiyoshi T (1996) Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Cancer Immunol Immunother 43:220–225CrossRefPubMed

42.

Ragnhammar P, Fagerberg J, Frodin JE, Hjelm AL, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced. Int J Cancer 53:751–758PubMed

43.

Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T, Schmidt-Wolf I (1999) Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. Hybridoma 18:63–68PubMed

Titel: Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study
verfasst von: A. P. Zbar
H. Thomas
R. W. Wilkinson
M. Wadhwa
K. N. Syrigos
E. L. Ross
P. Dilger
T. G. Allen-Mersh
W. A. Kmiot
A. A. Epenetos
D. Snary
W. F. Bodmer
Publikationsdatum: 01.09.2005
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 5/2005
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-004-0726-x

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background and aims

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2005

IgA nephropathy in association with Crohn’s disease

Double frameshift mutations in APC and MSH2 in the same individual

Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer

Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy

Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision

A case of pneumatosis cystoides intestinalis with dermatomyositis in which EUS was useful for the diagnosis

Update Chirurgie